ESC - European Society of Cardiology
ESC - European Society of Cardiology
09/01/2024 | Press release | Distributed by Public on 09/01/2024 04:55
Improved outcomes with mineralocorticoid receptor antagonists across different types of heart failure
Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2024. It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 (0) 6 61 40 18 84
Email: [email protected]
The hashtag for ESC Congress 2024 is #ESCCongress
Follow us on X @ESCardioNews
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
Funding: There was no funding source for the meta-analysis. The RALES trial was supported by a grant from Searle Pharmaceuticals, the EMPHASIS-HF trial was sponsored by Pfizer, the TOPCAT trial was supported by the National Heart Lung Blood Institute, USA, and the FINEARTS-HF trial was sponsored by Bayer AG.
Disclosures: Pardeep Jhund reports speakers' fees from AstraZeneca, Novartis, Alkem Metabolics, ProAdWise Communications, Sun Pharmaceuticals; advisory board fees from AstraZeneca, Boehringer Ingelheim, Novartis; research funding from AstraZeneca, Boehringer Ingelheim, Analog Devices Inc, Roche Diagnostics. PSJ's employer the University of Glasgow has been remunerated for clinical trial work from AstraZeneca, Bayer AG, Novartis and Novo Nordisk. He is a Director at GCTP Ltd.
References and notes
1'MRAs in heart failure - An individual patient data meta-analysis of randomised trials' will be discussed during Hot Line 7 on Sunday 1 September in room London.
2Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
3Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364: 11-21.
4Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370:1383-1392.
5'FINEARTS-HF - Finerenone in heart failure with mildly reduced and preserved ejection fraction' will be discussed during Hot Line 7 on Sunday 1 September in room London.
It is the world's largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in London and online - from 30 August to 2 September. Explore the scientific programme. More information is available from the ESC Press Office at [email protected].
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.